Perceptive Advisors
Perceptive Advisors is a private investment management firm managing approximately $8 billion in life sciences-focused assets across hedge fund, private credit, structured financing, and venture capital strategies, serving healthcare companies throughout the capital structure.
- Company typePrivate
- Founded1999
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Perceptive Advisors does
Perceptive Advisors is a privately held investment management firm founded in 1999 by Joseph Edelman and headquartered in New York, focused exclusively on the life sciences and healthcare sectors. The firm manages approximately $8 billion in assets under management as of October 2025 with a 47-person team that includes in-house PhDs, MDs, molecular biologists, and technologists who conduct fundamental scientific due diligence on healthcare opportunities across the capital structure. Perceptive's investment approach emphasizes deep technical evaluation combined with long-term capital partnership, targeting innovation in biotechnology, drugs, medical devices, diagnostics, digital health, and life sciences research tools.
Perceptive operates four core investment strategies: the Perceptive Life Sciences Fund (a 25+ year hedge fund focused on small- to mid-cap public equities, crossover rounds, and IPO/follow-on financings), Perceptive Credit Opportunities Funds (private credit strategy launched in 2014 with approximately $3.5 billion raised, providing customized $20–$300 million debt facilities to healthcare companies), Perceptive Capital Solutions (a flexible structured-financing platform serving commercial-stage biopharma and medtech), and the Perceptive Xontogeny Venture Fund (early-stage venture capital with $700M+ in dedicated capital, leading or co-leading $10–$50 million Series A rounds). The firm additionally sponsors Perceptive Capital Solutions Corp (PCSC), a SPAC vehicle, and has expanded into direct operational ownership of healthcare platforms (Synthego, Vapotherm).
Perceptive's revenue model is based on management fees and performance-based carried interest on its closed-end funds, supplemented by interest income, warrants, and equity-linked returns from its private credit and structured financing activities. Distribution is conducted through direct institutional investment transactions, with global investment reach but no public marketing channels, consistent with a private investment firm. Investor access is restricted via password-protected portals (Northern Trust, SEI), and fund terms are negotiated privately with qualified LPs.
Perceptive Advisors firmographics
Firmographics- Name
- Perceptive Advisors
- Legal name
- Perceptive Advisors, LLC
- Website
- http://www.perceptivelife.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Perceptive Advisors is a private investment management firm managing approximately $8 billion in life sciences-focused assets across hedge fund, private credit, structured financing, and venture capital strategies, serving healthcare companies throughout the capital structure.
- Ownership category
- akta.pro rank
Perceptive Advisors industry classification
Industry- Product category
- Life Sciences Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Venture Debt Providers (FSANAAAL)
- akta.pro secondary industry
- Large-Cap / Sponsor Finance Direct Lending (FSANADAJ)
Keywords
Where Perceptive Advisors is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Perceptive Advisors business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Asset Management / Investment Management Fees: Perceptive Advisors generates revenue through management fees and performance-based carried interest on approximately $8 billion in assets under management across multiple closed-end funds (Life Sciences Fund, Credit Opportunities Funds, Xontogeny Venture Funds). Fees are earned on capital committed and deployed across public equities, private credit, venture, and structured capital solutions strategies.
- Structured Capital Solutions Income: Perceptive Capital Solutions provides structured financing to life sciences companies (e.g., $60 million credit facility to Pulmonx, $70 million credit facility to TELA Bio, $60 million to AVITA Medical), generating interest income, warrants, and equity-linked returns.
- Private Credit Interest Income: Credit Opportunities Funds deploy approximately $3.5 billion of capital into customized debt financing solutions, earning interest income (e.g., Term SOFR plus 7.0% with floor on Pulmonx facility) and warrants on minimally-dilutive loans to healthcare companies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Investment funds with non-publicly disclosed terms |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels3 records
Perceptive Advisors product offering
Product offeringCore offering
Perceptive Advisors is a multi-strategy life sciences and healthcare investment management firm that invests across the capital structure via four closed-end fund strategies: a public-equity Life Sciences Fund, a private Credit Opportunities Fund, a Capital Solutions structured financing platform, and a Venture Capital (Xontogeny) fund for early-stage seed and Series A deals. The firm manages approximately $8 billion in assets and supports healthcare companies from discovery through commercialization, with investments sized from $10 million in venture rounds up to $300 million in credit transactions. It also sponsors a SPAC (Perceptive Capital Solutions Corp) and structures PIPEs, royalty deals and convertible financings for biopharma, medical device, diagnostics and digital health companies.
Product overview
Perceptive Advisors operates a multi-strategy platform-plus-modules architecture for life sciences investing rather than a single unified product. The core offering comprises four complementary investment strategies — the Perceptive Life Sciences Fund (PLSF) hedge fund, the Perceptive Credit Opportunities Fund for private credit, Perceptive Capital Solutions (PCS) for structured financing, and the Perceptive Xontogeny Venture Fund for early-stage venture capital — which together allow the firm to support life sciences companies across the capital structure and throughout their life cycle. On top of this, Perceptive Capital Solutions Corp (PCSC) serves as a SPAC vehicle sponsored by the firm to access public markets. These strategies collectively enable investments in public equities, private credit, structured financing, venture financings and SPAC-led public listings for biopharma, medtech, diagnostics, digital health and life sciences tools companies.
Differentiator
Problem solved
Functional benefit
Brands
- Perceptive Life Sciences Fund: Flagship public-equity focused strategy making global investments in biotechnology, drugs, medical devices and diagnostics across small- to mid-cap companies.
- Perceptive Credit Opportunities Funds
- Perceptive Capital Solutions (PCS)
- Perceptive Xontogeny Venture Fund
Products and services
- Perceptive Life Sciences Fund (PLSF) Long-running life sciences-focused hedge fund strategy making global investments in public and private companies developing biotechnology products, drugs, medical devices and diagnostics; invests throughout a company's life cycle including growth-stage investments, crossover rounds, IPOs and public follow-on financings, primarily in small to mid-capitalization publicly-traded companies using a fundamental scientific approach.
- Perceptive Credit Opportunities Fund Private credit strategy providing customized debt financing solutions to innovative healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health and life sciences research; invests $20-$300 million per investment as minimally-dilutive growth capital.
- Perceptive Capital Solutions (PCS) Flexible capital platform providing structured financing solutions to commercial-stage and late-stage clinical biopharma and medical technology companies; delivers tailored capital that supports growth, strategic initiatives and balance sheet optimization across debt, equity-linked and structured instruments.
- Perceptive Xontogeny Venture Fund Venture capital strategy with two closed-end funds (Fund I launched 2018, Fund II closed 2021) managing over $700 million of capital dedicated to financing early-stage life sciences companies; provides lead or co-lead Series A and select growth-stage financings with investments of $10-$50 million across biotechnology, medtech, healthtech, digital health and healthcare tools/services.
- Perceptive Capital Solutions Corp (PCSC) Special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, formed to pursue business combinations in healthcare and healthcare-related industries.
Quantifiable outcome
- Flagship fund returned 75% in 2025
- +5 more outcomes
Companies that use Perceptive Advisors
Customer profileNamed customers1 record
Ideal customer profiles5 records
Perceptive Advisors technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Perceptive Advisors partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Freenome HoldingsflagshipPerceptive Capital Solutions Corp (PCSC), a SPAC sponsored by Perceptive Advisors, is merging with Freenome in a $1.1B transaction with $240M PIPE (led by Perceptive Advisors and RA Capital, with Bain Capital Life Sciences and Farallon); combined entity will rename Freenome, Inc. (Nasdaq: FRNM) to commercialize blood-based cancer detection tests.
- RA Capital ManagementcoreRA Capital Management sponsors Research Alliance Corporation III (SPAC, ticker RACC) which priced a $75M IPO with Perceptive Advisors among institutional investors; close co-investment relationship across multiple transactions.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Perceptive Advisors competitors and assessment
Company assessmentBroad incumbents
- Janus Henderson Investors: Large diversified asset manager with a meaningful healthcare franchise; co-investor with Perceptive on Sutro Biopharma, Solid Biosciences, Quince — broader mandate but overlapping deal participation.
- Balyasny Asset Management: Multi-strategy hedge fund with a significant dedicated healthcare team; co-led Opus Genetics and Quince financings with Perceptive — broader mandate but overlapping healthcare book.
Direct peers
- Cormorant Asset Management: Healthcare-focused hedge fund investing across public and private life sciences — overlaps with Perceptive's public-equity and PIPE activity (Adlai Nortye, Quince).
- Bain Capital Life Sciences: Dedicated healthcare PE/VC platform; frequently co-leads with Perceptive on AavantiBio, Imperative Care and Solid Biosciences — comparable stage range and biotech mandate.
- Baker Bros. Advisors: Long-running biotech-focused investment manager with public-equity and private financing arms; closely comparable to Perceptive Life Sciences Fund in mandate, style and scientific orientation.
- OrbiMed Advisors: Largest dedicated healthcare investment firm across public/private equity, private credit and royalties — directly comparable multi-strategy healthcare platform with comparable AUM scale.
- Foresite Capital: Healthcare-focused investment firm investing across public and private life sciences with scientific orientation; recent co-investor with Perceptive on Quince Therapeutics.
- RA Capital Management: Healthcare-focused crossover fund that co-leads and co-invests with Perceptive across PIPE, SPAC (RACC), and private rounds (Freenome, Capstan, Solid Biosciences, AavantiBio) — directly comparable strategy and LP base.
- Deerfield Management: Healthcare-dedicated investment manager offering equity, credit and structured financing to life sciences companies — directly comparable to Perceptive's multi-strategy architecture.
Emerging players
- EcoR1 Capital: Biotech-focused crossover fund led by Oleg Nodelman; comparable mandate on public/private biotech investing with somewhat smaller AUM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Perceptive Advisors social profiles
Digital presencePerceptive Advisors financial estimates
Financial estimateRevenue estimate
Valuation estimate
Perceptive Advisors leadership team
Management profileNumber of profiles
Profiles9 records
Perceptive Advisors subsidiaries and ownership
Company hierarchySubsidiaries4 records
Perceptive Advisors funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Perceptive Advisors M&A and investment
M&A and investmentM&A2 records
Investments381 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Perceptive Advisors
What does Perceptive Advisors do?
Perceptive Advisors is a multi-strategy life sciences and healthcare investment management firm that invests across the capital structure via four closed-end fund strategies: a public-equity Life Sciences Fund, a private Credit Opportunities Fund, a Capital Solutions structured financing platform, and a Venture Capital (Xontogeny) fund for early-stage seed and Series A deals. The firm manages approximately $8 billion in assets and supports healthcare companies from discovery through commercialization, with investments sized from $10 million in venture rounds up to $300 million in credit transactions. It also sponsors a SPAC (Perceptive Capital Solutions Corp) and structures PIPEs, royalty deals and convertible financings for biopharma, medical device, diagnostics and digital health companies.
Is Perceptive Advisors a public or private company?
Perceptive Advisors is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Perceptive Advisors founded?
Perceptive Advisors was founded in 1999. It employs 11 to 50 people.
Where is Perceptive Advisors based?
Perceptive Advisors is headquartered in New York, United States, in the North America region.
How does Perceptive Advisors make money?
Three revenue lines are on record. Asset Management / Investment Management Fees are the primary driver. The others are structured Capital Solutions Income and private Credit Interest Income.
Who are Perceptive Advisors's main competitors?
Broad incumbents on record are Janus Henderson Investors and Balyasny Asset Management. Direct peers are Cormorant Asset Management, Bain Capital Life Sciences, Baker Bros. Advisors, OrbiMed Advisors, Foresite Capital, RA Capital Management and Deerfield Management. EcoR1 Capital is listed as an emerging player.
Does Perceptive Advisors have an API?
No public API is recorded for Perceptive Advisors.
What industry is Perceptive Advisors in?
Perceptive Advisors's product category is Life Sciences Investment Management. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers, with a secondary code of FSANADAJ, Large-Cap / Sponsor Finance Direct Lending. Its NAICS code is 523940 and its SIC code is 6282.